Fairvalue-Calculator Fairvalue-Calculator

Fisher & Paykel Healthcare Corporation (FSPKF) Fair Value & Analysis

Healthcare · US · Market cap $14.2B

Price$22.52
Fair Value$10.05
Upside-55.4%
Quality97/100
Evidence: High Range $6.97 – $12.56

Analysis

Fisher & Paykel Healthcare Corporation (FSPKF) currently trades at $22.52, while our model-based Fair Value estimate is $10.05 — implying the stock looks roughly 55.4% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, an…

Open the full interactive analysis →

Similar stocks

Intuitive Surgical, Inc (ISRG) -61% EssilorLuxottica Société anonyme (ESLOF) -34% HOYA Corporation (HOCPY) -38% Medline Inc (MDLN) -5% Becton, Dickinson and Company (BDX) -16% Alcon Inc (ALC) -44%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.